nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—ADRB2—polycystic ovary syndrome	0.771	1	CbGaD
Salmeterol—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0127	0.0988	CcSEcCtD
Salmeterol—Sinus headache—Metformin—polycystic ovary syndrome	0.0102	0.0791	CcSEcCtD
Salmeterol—Sinus congestion—Metformin—polycystic ovary syndrome	0.00667	0.0518	CcSEcCtD
Salmeterol—Toothache—Metformin—polycystic ovary syndrome	0.00545	0.0424	CcSEcCtD
Salmeterol—Upset stomach—Metformin—polycystic ovary syndrome	0.00506	0.0393	CcSEcCtD
Salmeterol—Heartburn—Metformin—polycystic ovary syndrome	0.00482	0.0375	CcSEcCtD
Salmeterol—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00409	0.0318	CcSEcCtD
Salmeterol—Contusion—Metformin—polycystic ovary syndrome	0.0038	0.0295	CcSEcCtD
Salmeterol—Chest discomfort—Metformin—polycystic ovary syndrome	0.00375	0.0291	CcSEcCtD
Salmeterol—Arbutamine—ADRB3—polycystic ovary syndrome	0.0034	0.366	CrCbGaD
Salmeterol—Ear pain—Metformin—polycystic ovary syndrome	0.00282	0.0219	CcSEcCtD
Salmeterol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00264	0.0205	CcSEcCtD
Salmeterol—Injury—Metformin—polycystic ovary syndrome	0.00262	0.0204	CcSEcCtD
Salmeterol—Labetalol—ADRB3—polycystic ovary syndrome	0.00241	0.26	CrCbGaD
Salmeterol—Pain in extremity—Metformin—polycystic ovary syndrome	0.00241	0.0187	CcSEcCtD
Salmeterol—Migraine—Metformin—polycystic ovary syndrome	0.00237	0.0184	CcSEcCtD
Salmeterol—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.0022	0.0171	CcSEcCtD
Salmeterol—Cramp muscle—Metformin—polycystic ovary syndrome	0.00217	0.0168	CcSEcCtD
Salmeterol—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00215	0.0167	CcSEcCtD
Salmeterol—Influenza—Metformin—polycystic ovary syndrome	0.00208	0.0162	CcSEcCtD
Salmeterol—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00199	0.0155	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00193	0.015	CcSEcCtD
Salmeterol—Infestation—Metformin—polycystic ovary syndrome	0.00186	0.0144	CcSEcCtD
Salmeterol—Infestation NOS—Metformin—polycystic ovary syndrome	0.00186	0.0144	CcSEcCtD
Salmeterol—Rhinitis—Metformin—polycystic ovary syndrome	0.00167	0.013	CcSEcCtD
Salmeterol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00164	0.0127	CcSEcCtD
Salmeterol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00155	0.012	CcSEcCtD
Salmeterol—Immune system disorder—Metformin—polycystic ovary syndrome	0.0015	0.0117	CcSEcCtD
Salmeterol—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0015	0.0117	CcSEcCtD
Salmeterol—Malnutrition—Metformin—polycystic ovary syndrome	0.00145	0.0113	CcSEcCtD
Salmeterol—Muscle spasms—Metformin—polycystic ovary syndrome	0.00139	0.0108	CcSEcCtD
Salmeterol—Tremor—Metformin—polycystic ovary syndrome	0.00136	0.0106	CcSEcCtD
Salmeterol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00135	0.0105	CcSEcCtD
Salmeterol—Malaise—Metformin—polycystic ovary syndrome	0.00131	0.0102	CcSEcCtD
Salmeterol—Arbutamine—ADRB2—polycystic ovary syndrome	0.00129	0.139	CrCbGaD
Salmeterol—Palpitations—Metformin—polycystic ovary syndrome	0.00128	0.00996	CcSEcCtD
Salmeterol—Salbutamol—ADRB2—polycystic ovary syndrome	0.00125	0.135	CrCbGaD
Salmeterol—Hypertension—Metformin—polycystic ovary syndrome	0.00125	0.00973	CcSEcCtD
Salmeterol—Myalgia—Metformin—polycystic ovary syndrome	0.00123	0.00959	CcSEcCtD
Salmeterol—Chest pain—Metformin—polycystic ovary syndrome	0.00123	0.00959	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00123	0.00953	CcSEcCtD
Salmeterol—Discomfort—Metformin—polycystic ovary syndrome	0.00122	0.00948	CcSEcCtD
Salmeterol—Oedema—Metformin—polycystic ovary syndrome	0.00118	0.0092	CcSEcCtD
Salmeterol—Infection—Metformin—polycystic ovary syndrome	0.00118	0.00914	CcSEcCtD
Salmeterol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00116	0.00902	CcSEcCtD
Salmeterol—Skin disorder—Metformin—polycystic ovary syndrome	0.00115	0.00893	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00108	0.00838	CcSEcCtD
Salmeterol—Paraesthesia—Metformin—polycystic ovary syndrome	0.00106	0.00826	CcSEcCtD
Salmeterol—Dyspnoea—Metformin—polycystic ovary syndrome	0.00106	0.0082	CcSEcCtD
Salmeterol—Dyspepsia—Metformin—polycystic ovary syndrome	0.00104	0.0081	CcSEcCtD
Salmeterol—Fatigue—Metformin—polycystic ovary syndrome	0.00102	0.00793	CcSEcCtD
Salmeterol—Constipation—Metformin—polycystic ovary syndrome	0.00101	0.00786	CcSEcCtD
Salmeterol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000975	0.00758	CcSEcCtD
Salmeterol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000968	0.00752	CcSEcCtD
Salmeterol—Urticaria—Metformin—polycystic ovary syndrome	0.00094	0.00731	CcSEcCtD
Salmeterol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000935	0.00727	CcSEcCtD
Salmeterol—Labetalol—ADRB2—polycystic ovary syndrome	0.000917	0.0989	CrCbGaD
Salmeterol—Asthenia—Metformin—polycystic ovary syndrome	0.000849	0.0066	CcSEcCtD
Salmeterol—Diarrhoea—Metformin—polycystic ovary syndrome	0.00081	0.00629	CcSEcCtD
Salmeterol—Dizziness—Metformin—polycystic ovary syndrome	0.000783	0.00608	CcSEcCtD
Salmeterol—Vomiting—Metformin—polycystic ovary syndrome	0.000752	0.00585	CcSEcCtD
Salmeterol—Rash—Metformin—polycystic ovary syndrome	0.000746	0.0058	CcSEcCtD
Salmeterol—Dermatitis—Metformin—polycystic ovary syndrome	0.000745	0.00579	CcSEcCtD
Salmeterol—Headache—Metformin—polycystic ovary syndrome	0.000741	0.00576	CcSEcCtD
Salmeterol—Nausea—Metformin—polycystic ovary syndrome	0.000703	0.00546	CcSEcCtD
Salmeterol—ADRB2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000111	0.00123	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000111	0.00123	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000108	0.00119	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LPCAT2—polycystic ovary syndrome	0.000105	0.00116	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SUOX—polycystic ovary syndrome	0.000105	0.00116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000104	0.00115	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000102	0.00113	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000102	0.00112	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000101	0.00112	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000101	0.00111	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.0001	0.00111	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	9.98e-05	0.0011	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	9.83e-05	0.00109	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	9.82e-05	0.00108	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	9.76e-05	0.00108	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ISYNA1—polycystic ovary syndrome	9.75e-05	0.00108	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—POMC—polycystic ovary syndrome	9.72e-05	0.00107	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP1A1—polycystic ovary syndrome	9.42e-05	0.00104	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	9.29e-05	0.00103	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	9.26e-05	0.00102	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—GHRL—polycystic ovary syndrome	9.1e-05	0.001	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FLT4—polycystic ovary syndrome	9e-05	0.000993	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	8.96e-05	0.000989	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	8.94e-05	0.000986	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	8.93e-05	0.000986	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	8.83e-05	0.000975	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	8.34e-05	0.00092	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TEAD2—polycystic ovary syndrome	8.29e-05	0.000915	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKR1C2—polycystic ovary syndrome	8.29e-05	0.000915	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NMNAT3—polycystic ovary syndrome	8.29e-05	0.000915	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	8.25e-05	0.00091	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	8.22e-05	0.000908	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	8.19e-05	0.000904	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP1A1—polycystic ovary syndrome	8.16e-05	0.000901	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—FSHR—polycystic ovary syndrome	8.13e-05	0.000898	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	8.05e-05	0.000888	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	7.89e-05	0.000871	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NPB—polycystic ovary syndrome	7.87e-05	0.000868	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—LHB—polycystic ovary syndrome	7.79e-05	0.00086	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	7.62e-05	0.000841	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	7.58e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LPCAT2—polycystic ovary syndrome	7.58e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SUOX—polycystic ovary syndrome	7.58e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	7.51e-05	0.000829	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	7.44e-05	0.000821	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	7.39e-05	0.000815	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—SCT—polycystic ovary syndrome	7.3e-05	0.000806	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	7.28e-05	0.000804	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NMNAT3—polycystic ovary syndrome	7.18e-05	0.000792	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	7.16e-05	0.000791	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	7.11e-05	0.000785	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—LHB—polycystic ovary syndrome	7.08e-05	0.000781	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ISYNA1—polycystic ovary syndrome	7.05e-05	0.000778	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—POMC—polycystic ovary syndrome	7.02e-05	0.000775	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—GNAS—polycystic ovary syndrome	6.99e-05	0.000771	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	6.97e-05	0.000769	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PNPLA2—polycystic ovary syndrome	6.95e-05	0.000767	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	6.92e-05	0.000763	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	6.88e-05	0.000759	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	6.87e-05	0.000758	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	6.85e-05	0.000756	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	6.77e-05	0.000748	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	6.69e-05	0.000739	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	6.63e-05	0.000732	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SRD5A1—polycystic ovary syndrome	6.58e-05	0.000727	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SUOX—polycystic ovary syndrome	6.57e-05	0.000725	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LPCAT2—polycystic ovary syndrome	6.57e-05	0.000725	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	6.56e-05	0.000725	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	6.56e-05	0.000725	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	6.48e-05	0.000716	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	6.33e-05	0.000698	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—STAR—polycystic ovary syndrome	6.28e-05	0.000693	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	6.18e-05	0.000682	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	6.15e-05	0.000679	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	6.14e-05	0.000678	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ISYNA1—polycystic ovary syndrome	6.1e-05	0.000674	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—POMC—polycystic ovary syndrome	6.08e-05	0.000672	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKR1C2—polycystic ovary syndrome	5.99e-05	0.000661	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TEAD2—polycystic ovary syndrome	5.99e-05	0.000661	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	5.97e-05	0.000659	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	5.96e-05	0.000658	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	5.8e-05	0.00064	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	5.65e-05	0.000624	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMMR—polycystic ovary syndrome	5.6e-05	0.000618	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	5.57e-05	0.000615	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	5.43e-05	0.0006	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	5.36e-05	0.000592	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HSD3B1—polycystic ovary syndrome	5.34e-05	0.00059	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	5.28e-05	0.000583	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.28e-05	0.000582	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TEAD2—polycystic ovary syndrome	5.19e-05	0.000573	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKR1C2—polycystic ovary syndrome	5.19e-05	0.000573	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5.14e-05	0.000568	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PNPLA2—polycystic ovary syndrome	5.02e-05	0.000554	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.99e-05	0.000551	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.91e-05	0.000542	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LHB—polycystic ovary syndrome	4.87e-05	0.000538	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	4.81e-05	0.00053	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HSD3B2—polycystic ovary syndrome	4.76e-05	0.000526	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SRD5A1—polycystic ovary syndrome	4.76e-05	0.000525	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	4.7e-05	0.000519	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.67e-05	0.000516	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKR1C1—polycystic ovary syndrome	4.61e-05	0.000509	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—STAR—polycystic ovary syndrome	4.54e-05	0.000501	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.52e-05	0.000499	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.39e-05	0.000485	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.38e-05	0.000484	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PNPLA2—polycystic ovary syndrome	4.35e-05	0.00048	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.32e-05	0.000477	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	4.28e-05	0.000473	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SULT2A1—polycystic ovary syndrome	4.24e-05	0.000468	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.23e-05	0.000467	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	4.18e-05	0.000461	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	4.12e-05	0.000455	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—RRM2—polycystic ovary syndrome	4.11e-05	0.000454	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.09e-05	0.000451	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMMR—polycystic ovary syndrome	4.05e-05	0.000447	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—YAP1—polycystic ovary syndrome	3.96e-05	0.000437	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.96e-05	0.000437	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.95e-05	0.000436	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	3.93e-05	0.000434	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	3.92e-05	0.000432	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.89e-05	0.000429	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HSD3B1—polycystic ovary syndrome	3.86e-05	0.000426	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	3.85e-05	0.000425	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NAMPT—polycystic ovary syndrome	3.81e-05	0.00042	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP11A1—polycystic ovary syndrome	3.76e-05	0.000415	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.74e-05	0.000413	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	3.67e-05	0.000405	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	3.64e-05	0.000402	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.59e-05	0.000396	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKR1C3—polycystic ovary syndrome	3.55e-05	0.000392	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	3.52e-05	0.000389	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	3.52e-05	0.000389	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LHB—polycystic ovary syndrome	3.52e-05	0.000389	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	3.51e-05	0.000387	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP17A1—polycystic ovary syndrome	3.49e-05	0.000386	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HSD3B2—polycystic ovary syndrome	3.44e-05	0.00038	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	3.4e-05	0.000375	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	3.35e-05	0.00037	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	3.34e-05	0.000369	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKR1C1—polycystic ovary syndrome	3.33e-05	0.000368	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.31e-05	0.000365	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	3.28e-05	0.000362	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	3.27e-05	0.000361	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	3.21e-05	0.000354	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	3.13e-05	0.000346	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SULT2A1—polycystic ovary syndrome	3.07e-05	0.000339	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	3.05e-05	0.000337	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.05e-05	0.000336	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TH—polycystic ovary syndrome	3.02e-05	0.000334	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3e-05	0.000331	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	2.98e-05	0.000329	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—RRM2—polycystic ovary syndrome	2.97e-05	0.000328	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	2.97e-05	0.000328	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC2A4—polycystic ovary syndrome	2.94e-05	0.000325	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	2.89e-05	0.000319	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—YAP1—polycystic ovary syndrome	2.86e-05	0.000316	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	2.79e-05	0.000307	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	2.79e-05	0.000307	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP19A1—polycystic ovary syndrome	2.77e-05	0.000305	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.76e-05	0.000305	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.76e-05	0.000305	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	2.75e-05	0.000304	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	2.72e-05	0.0003	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.66e-05	0.000293	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	2.66e-05	0.000293	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.63e-05	0.000291	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	2.57e-05	0.000284	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.57e-05	0.000283	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	2.57e-05	0.000283	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.56e-05	0.000282	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	2.53e-05	0.000279	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	2.48e-05	0.000274	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GNAS—polycystic ovary syndrome	2.47e-05	0.000272	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.43e-05	0.000268	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.41e-05	0.000267	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	2.41e-05	0.000266	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	2.38e-05	0.000263	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.37e-05	0.000262	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	2.35e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NCOR1—polycystic ovary syndrome	2.35e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.34e-05	0.000258	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	2.33e-05	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.32e-05	0.000256	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A1—polycystic ovary syndrome	2.23e-05	0.000246	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	2.22e-05	0.000245	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	2.21e-05	0.000244	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	2.19e-05	0.000242	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TH—polycystic ovary syndrome	2.19e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	2.13e-05	0.000235	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.12e-05	0.000234	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.11e-05	0.000233	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	2.08e-05	0.000229	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.02e-05	0.000223	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	2e-05	0.000221	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.98e-05	0.000219	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TH—polycystic ovary syndrome	1.89e-05	0.000209	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.88e-05	0.000208	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	1.84e-05	0.000203	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.79e-05	0.000198	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	1.78e-05	0.000197	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	1.73e-05	0.000191	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	1.7e-05	0.000188	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.7e-05	0.000187	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	1.68e-05	0.000186	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	1.66e-05	0.000183	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.66e-05	0.000183	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—INS—polycystic ovary syndrome	1.65e-05	0.000182	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.64e-05	0.000181	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	1.61e-05	0.000178	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.6e-05	0.000177	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.55e-05	0.000171	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	1.55e-05	0.000171	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	1.5e-05	0.000166	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.48e-05	0.000163	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	1.47e-05	0.000163	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	1.43e-05	0.000157	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.43e-05	0.000157	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	1.42e-05	0.000157	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	1.4e-05	0.000154	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.38e-05	0.000152	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.37e-05	0.000151	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.37e-05	0.000151	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.33e-05	0.000147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.3e-05	0.000144	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	1.3e-05	0.000144	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.28e-05	0.000141	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.26e-05	0.000139	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	1.22e-05	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	1.2e-05	0.000133	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—INS—polycystic ovary syndrome	1.19e-05	0.000132	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.19e-05	0.000132	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.17e-05	0.00013	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	1.05e-05	0.000116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.05e-05	0.000116	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	1.04e-05	0.000115	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—INS—polycystic ovary syndrome	1.03e-05	0.000114	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.02e-05	0.000112	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	9.88e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	9.29e-06	0.000103	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.96e-06	9.89e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	8.29e-06	9.16e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	7.9e-06	8.72e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	7.49e-06	8.27e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	6.98e-06	7.71e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	6.2e-06	6.84e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	5.66e-06	6.25e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	5.58e-06	6.17e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—INS—polycystic ovary syndrome	5.55e-06	6.13e-05	CbGpPWpGaD
